BioMarin Pharmaceutical | BMRN

Stock Price
57.77
Daily Change
1.02 1.80%
Monthly
-4.78%
Yearly
-31.29%
Q3 Forecast
57.29

Peers Price Chg Day Year Date
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
Agios Pharmaceuticals 36.01 -0.12 -0.33% -16.80% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Bayer 28.16 -0.42 -1.47% -1.83% Sep/06
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Insmed 145.10 2.57 1.80% 104.25% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 46.50 1.18 2.60% -19.47% Sep/05
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
United Therapeutics 400.52 20.05 5.27% 15.88% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05

BioMarin Pharmaceutical traded at $57.77 this Friday September 5th, increasing $1.02 or 1.80 percent since the previous trading session. Looking back, over the last four weeks, BioMarin Pharmaceutical gained 4.78 percent. Over the last 12 months, its price fell by 31.29 percent. Looking ahead, we forecast BioMarin Pharmaceutical to be priced at 57.29 by the end of this quarter and at 55.88 in one year, according to Trading Economics global macro models projections and analysts expectations.

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.